Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Santiago De Compostela – page 53

690 clinical trials in Santiago De Compostela, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Santiago De Compostela at a glance
690
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

690 trials in Santiago De Compostela

Open in trial search

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer metastatic

Not recruiting

Study of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Mantle cell lymphoma

Not recruiting

Study of Acalabrutinib, Venetoclax, and Rituximab for Patients with Newly Diagnosed Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Hypercholesterolaemia

Not recruiting

Study on the Effectiveness and Safety of MK-0616 for Adults with High Cholesterol

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide Chloride
  • Sponsor:Merck Sharp & Dohme LLC

Transitional cell cancer of the renal pelvis and ureter

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gilead Sciences Inc.

Non-small cell lung cancer+1

Not recruiting

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dyslipidaemia

Not recruiting

Study on the Effects of AZD0780 on Cholesterol Levels in Adults Aged 18-75 with Dyslipidemia

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:1-[6-[[(1S,3S)-3-[[5-(Difluoromethoxy)Pyrimidin-2-Yl]Amino]Cyclopentyl]Amino]Pyridin-3-Yl]Pyridin-2-One
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Samsung Bioepis Co. Ltd.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Solti Group

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Gastrointestinal stromal tumour

Not recruiting

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Ornithine transcarbamoylase deficiency

Not recruiting

Long-Term Study on the Safety of Avalotcagene Ontaparvovec for Adults with Late-Onset Ornithine Transcarbamylase Deficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avalotcagene Ontaparvovec
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Santiago De Compostela

What the registry says about research in the country

01 Respiratory Infections Research

Innovative studies focusing on respiratory viral infections, including trials for RSV, influenza, and COVID-19 vaccines. Research aims to enhance protection in vulnerable populations, particularly adults over 60.

  • RSV and hMPV vaccine development
  • Influenza vaccine efficacy studies
  • COVID-19 vaccine co-administration research

Multiple trials evaluating both single and combination vaccine approaches for respiratory diseases.

02 Cardiovascular Studies

Research targeting cardiovascular health and prevention, with emphasis on innovative treatments for stroke and heart failure. Studies include both therapeutic interventions and preventive measures.

  • Acute cerebral ischemic stroke treatment
  • Heart failure prevention strategies
  • Cardiovascular risk management

Focus on developing new therapeutic approaches for better patient outcomes.

03 Dermatological Research

Advanced clinical investigations in dermatological conditions, particularly focusing on moderate to severe cases of psoriasis and atopic dermatitis.

  • Plaque psoriasis treatments
  • Psoriatic arthritis therapies
  • Atopic dermatitis interventions

Trials evaluating novel therapeutic agents for chronic skin conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.